ID   KH-100
AC   CVCL_D5CY
DR   Wikidata; Q127382418
RX   CelloPub=CLPUB00761;
CC   Population: Caucasian.
CC   Doubling time: 26 hours (CelloPub=CLPUB00761).
CC   Selected for resistance to: ChEBI; CHEBI:44423; Hydroxyurea.
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_D5CX ! KH-85
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 02-05-24; Last updated: 10-09-24; Version: 2
//
RX   CelloPub=CLPUB00761;
RA   Carman M.D.;
RT   "Altered and increased ribonucleotide reductase activity as a
RT   mechanism of resistance to hydroxyurea in a human myelogenous leukemia
RT   cell line.";
RL   Thesis PhD (1988); Yale University; New Haven; USA.
//